Loss of ten-eleven translocation 2 (TET2) facilitates aggressive behaviour in cutaneous melanoma by inducing peroxisome proliferator-activated receptor-γ coactivator 1α expression and oxidative phosphorylation
British Journal of Dermatology · 06.01.2026 · 194 (1) · 111-124
DOI: 10.1093/bjd/ljaf378 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 27.09.2025. Verfasst von Grant M Fischer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Melanoma, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Skin Neoplasms, DNA-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Stanley Robbins Memorial Research Fund of Brigham.
Abstract (Originalsprache)
Background
The induction of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α; encoded by PPARGC1A) expression and activation of oxidative phosphorylation (OXPHOS) is associated with disease progression and treatment resistance in patients with cutaneous melanoma. Loss of the TET2 (ten-eleven translocation 2)/5-hydroxymethylcytosine (5-hmC) epigenetic pathway is linked to melanoma aggressiveness, although the underlying mechanisms remain unclear.
Objectives
To explore a relationship between TET2-mediated DNA hydroxymethylation and the induction of PPARGC1A/PGC-1α expression and activation of OXPHOS in melanoma.
Methods
RNA sequencing data from 368 melanoma metastases and 102 primary melanoma tumours were analysed, with tumours categorized as ‘TET2-low’ or ‘TET2-high’, based on TET2 gene expression. Differential gene expression and gene set enrichment analyses were done, with further validation using a tissue microarray comprised of 33 clinical specimens and a publicly available gene expression dataset from 209 primary tumours. Confirmatory in vitro and in vivo studies were performed using melanoma cell lines with altered TET2 and PGC-1α expression. 5-hmC and 5-methylcytosine levels at PPARGC1A were assessed using hydroxymethylated (hMeDIPseq) and methylated DNA immunoprecipitation sequencing.
Results
PGC-1α expression and activation of OXPHOS were significantly upregulated in TET2-low metastases and primary tumours. Tissue microarray analysis and gene expression studies showed an inverse relationship between TET2/5-hmC and PPARGC1A/PGC-1α expression and OXPHOS. In vitro and in vivo, PPARGC1A/PGC-1α expression and activation of OXPHOS was higher in TET2-low cells. hMeDIPseq identified significantly lower 5-hmC levels at an upstream PPARGC1A active enhancer in melanoma compared with naevi, in TET2-low compared with TET2-high cells and in cells expressing catalytically inactive TET2 compared with cells expressing wildtype TET2. Inhibition of PGC-1α expression and activation of OXPHOS mitigated migration and invasion in vitro and metastasis in vivo; TET2 loss was associated with resistance to mitogen-activated protein kinase (MAPK) pathway inhibition and enhanced sensitivity to OXPHOS inhibition.
Conclusions
Loss of TET2 promotes activation of PGC-1α/OXPHOS in melanoma, driving metabolic reprogramming that supports tumour progression and resistance to MAPK inhibition in a subset of tumours. Importantly, this phenotype renders TET2-deficient melanomas selectively vulnerable to OXPHOS inhibition, identifying an actionable therapeutic opportunity. These findings establish an epigenetic–metabolic axis as a critical determinant of melanoma aggressiveness and highlight TET2/5-hmC as a potential biomarker and a targetable pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Grant M Fischer, Rui Fang, Shuyun Xu, Anastasia I Karkempetzaki, Laure Migayron, Elizabeth Draper, Justina Wang, Tobias Schatton, Anna Mandinova, George F Murphy, Christine G Lian
Förderung
- NCI NIH HHS
- NIH HHS
- Stanley Robbins Memorial Research Fund of Brigham
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Fischer, G. M., Fang, R., Xu, S., Karkempetzaki, A. I., Migayron, L., Draper, E., Wang, J., Schatton, T., Mandinova, A., Murphy, G. F., & Lian, C. G. (2026). Loss of ten-eleven translocation 2 (TET2) facilitates aggressive behaviour in cutaneous melanoma by inducing peroxisome proliferator-activated receptor-γ coactivator 1α expression and oxidative phosphorylation. British Journal of Dermatology, 194(1), 111-124. https://doi.org/10.1093/bjd/ljaf378
Vancouver
Fischer GM, Fang R, Xu S, Karkempetzaki AI, Migayron L, Draper E, et al. Loss of ten-eleven translocation 2 (TET2) facilitates aggressive behaviour in cutaneous melanoma by inducing peroxisome proliferator-activated receptor-γ coactivator 1α expression and oxidative phosphorylation. British Journal of Dermatology. 2026;194(1):111-124. doi:10.1093/bjd/ljaf378
BibTeX
@article{Fischer2026,
author = {Fischer, Grant M and Fang, Rui and Xu, Shuyun and Karkempetzaki, Anastasia I and Migayron, Laure and Draper, Elizabeth and Wang, Justina and Schatton, Tobias and Mandinova, Anna and Murphy, George F and Lian, Christine G},
title = {Loss of ten-eleven translocation 2 (TET2) facilitates aggressive behaviour in cutaneous melanoma by inducing peroxisome proliferator-activated receptor-γ coactivator 1α expression and oxidative phosphorylation},
journal = {British Journal of Dermatology},
year = {2026},
volume = {194},
number = {1},
pages = {111--124},
doi = {10.1093/bjd/ljaf378}
}
EUVIMED